Inspyr Therapeutics Inc (OTCMKTS: NSPX) is making a big move up the charts since reversing off $0.0015 lows. The stock has quickly attracted a fast growing shareholder base that continues to bid NSPX higher. The stock got a big boost after being featured in this pr.
NSPX has been attracting some power traders in small caps and its easy to see why; Mipsagargin, Inspyr lead drug candidate, has been studied in a Phase 2 clinical trial in patients with Nexavar®-refractory hepatocellular carcinoma (HCC) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. The Company recently issued a $250k convertible debenture under favorable terms with a friendly investor.
Inspyr Therapeutics Inc (OTCMKTS: NSPX) is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr has strategically expanded its portfolio to include 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and Asia Pacific.
Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.
To Find out the inside Scoop on NSPX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
According to online sources, mipsagargin is a first-in-class PSMA-targeted prodrug that may be an effective therapeutic strategy in patients with HCC, a disease characterized as highly vascularized. Infusion of 40 mg/m2 mipsagargin over a 1-hour period on Days 1, 2 and 3 of 28-day cycles was relatively well tolerated and resulted in disease stabilization, decreased tumor blood flow as observed by decrease Ktrans, and prolonged TTP in a population of patients who had progressed on prior treatment with sorafenib. These observations importantly suggest that mipsagargin may have clinical activity in HCC, including in the population of patients with advanced, refractory HCC. In this study, exploratory analyses suggested that mipsagargin decreased blood flow in HCC lesions and in metastatic sites relative to baseline examination within two cycles of exposure to mipsagargin. These findings warrant a larger clinical study to further characterize the activity of mipsagargin in advanced HCC.
The following press release issued on March 24 has been a driver here: Inspyr Therapeutics: Can This High Potential Cancer Killing Biotech Repurpose Drugs to Help Fight COVID-19?
The pr mostly focused on Gilead had this to say on NSPX:
This leaves good reason to speculate that Inspyr Therapeutics can prove to be a pivotal player in the race to provide treatments to 100s of millions of people that may require treatment just in the United States alone over the coming months (or maybe years). Their technology and long list of patents may leverage their value to secure partner deal with a top biotech company like Gilead, Roche, and others currently working on treatments and vaccines, or increasing the probability for an outright acquisition of Inspyr.
Also, to note, the intellectual property (IP) supporting Inspyr Therapeutics (formerly known as GenSpera) technology was developed over 15 years at Johns Hopkins University and the University of Copenhagen with over $15 million in scientific grants from the National Cancer Institute, the U.S. Department of Defense, and the U.S. National Institutes of Health, among others. Their IP portfolio contains several issued patents and along with several pending patent applications. As reported by Crunchbase, Inspyr Therapeutics has raised $22.8 million.
— Inspyr Therapeutics (@InspyrTheraputx) March 18, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently running up the charts NSPX got some more fuel after a press release on Gilead speculated the Company “can prove to be a pivotal player in the race to provide treatments to 100s of millions of people that may require treatment just in the United States alone over the coming months (or maybe years). Their technology and long list of patents may leverage their value to secure partner deal with a top biotech company like Gilead, Roche, and others currently working on treatments and vaccines, or increasing the probability for an outright acquisition of Inspyr. The Company owns a patent portfolio which includes 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and Asia Pacific. We will be updating on NSPX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NSPX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in NSPX either long or short and we have not been compensated for this article.